Search Results
Your search for ,ITS matches 8694 pages
Showing 7201 - 7250Tadalafil Did Not Prevent Erectile Dysfunction Among Men Receiving Radiotherapy
Daily use of tadalafil (Cialis) did not improve erectile function compared to placebo or prevent erectile dysfunction among men undergoing radiotherapy for prostate cancer, according to results of a stratified, placebo-controlled, double-blind, parallel-group study with 1:1 randomization at 76...
Genitourinary Toxicity More Likely With Stereotactic Body Radiotherapy Than With Intensity-Modulated Radiotherapy
A retrospective analysis of patients with prostate cancer receiving primary treatment with either stereotactic body radiation therapy or intensity-modulated radiation therapy found that those receiving stereotactic body radiotherapy had greater rates of genitourinary toxicity during 2-year...
Breaking Bad News Badly Can Add to Upset
When the prognosis is poor, breaking the bad news badly can exacerbate the distress experienced by cancer patients and their families. A lack of sensitivity to patient and family emotions and not being attuned to how individual patients would prefer to be informed about their prognoses can result...
Inactivation of E3 Ubiquitin Ligase Cbl-b Allows Natural Killer Cells to Control Metastases
New therapeutic approaches to blocking inhibitory pathways of the immune system have raised hopes that such treatments might thwart development of metastases. In a study in Nature, Paolino and colleagues have shown that genetic deletion of the E3 ubiquitin ligase Cbl-b (casitas B-lineage...
Learning to Live in the Moment
I’ve been health conscious all my life. I have never smoked, I eat a healthy diet, and I have maintained a near-daily exercise routine since I was 20. I’m also steadfast about keeping yearly medical checkups and screenings. So when I felt a sharp, lightning-bolt of pain that went from the top of my ...
ASCO Cofounder Jane Cooke Wright, MD, Defied Racial/Gender Barriers and Helped Usher in the Modern Age of Chemotherapy
When Jane Cooke Wright, MD, met with six other oncologists at the Edgewater Beach Hotel in Chicago on April 9, 1964, to discuss the creation of American Society of Clinical Oncology, the first medical society dedicated to bringing patient-oriented issues to clinical oncology, the Civil Rights Act...
ASCO’s Visionary Founders
On April 9, 1964, seven physicians—Jane Cooke Wright, MD, FASCO; Arnoldus Goudsmit, MD, PhD; Fred J. Ansfield, MD, FASCO; Harry F. Bisel, MD, FASCO; Herman H. Freckman, MD, FASCO; Robert W. Talley, MD, FASCO; and William Wilson, MD, FASCO—met for lunch at the Edgewater Beach Hotel in Chicago. They...
The Consequence Is Cure
My Presidency was the first year that the Annual Meeting hit 10,000 attendees, which at the time we thought was a huge number—it seemed that we’d hit the ceiling. It was about 9 years after we published the results from our study of combination chemotherapy (MOPP) in the treatment of advanced...
Journal of Clinical Oncology
During my Presidency, we decided to increase ASCO’s size to give clinical investigators a better position in the medical world. To that end, I decided that the Society needed its own journal. At that time, we sent our papers to Blood or Cancer Research, where, in my estimation, they received poor...
Science vs Practice
My year as President was a busy one. Aside from continuing my research and directing the activities of the National Surgical Adjuvant Breast and Bowel Project, I was drowned by the vast amount of information that was sent to me by ASCO headquarters. At the onset of my Presidency, I discovered...
AACR–ASCO Transition
My Presidency was a transitional year; it was the first time that ASCO had a meeting separate from the American Association for Cancer Research. Since ASCO was thought to be simply a science-light organization that focused solely on clinical trials, the pressure was on to establish an independent...
One Community
My Presidential theme was One Community. I think that theme continues to express much of our goal in oncology, which is to make sure that all members of the cancer care team work together—oncologists, nurses, scientists, nutritionists, psychologists, social workers, administrators, and others. I...
Personalizing Cancer Care
Durng my Presidency we completely revamped the way the ASCO Board of Directors works by creating various subcommittees and a much more deliberate strategic planning process. In effect, the Board members took more ownership of ASCO’s agenda, planning the future of the Society rather than dealing...
Celebrating ASCO's History, 1964-2014
The last 50 years have been marked by significant advances in cancer research and in more effective therapy for patients. Once viewed as a largely untreatable, fatal disease, today a number of cancers are being converted into chronic diseases that can be managed for long periods of time. The result ...
The Leukemia & Lymphoma Society Surpasses $1 Billion Investment in Blood Cancer Research
The Leukemia & Lymphoma Society (LLS) has announced that it has passed the $1 billion mark in research investment, a significant milestone in the cancer research landscape as the Society continues its 65-year pursuit of advancing breakthrough therapies, finding cures, and ensuring access to...
An Oncologic Surgeon Discusses the Pros and Cons of Pursuing a Business Degree
Is pursuing a Master of Business Administration (MBA) degree a good idea for ambitious surgical oncologists who want to advance their careers? The ASCO Post recently spoke with Martin J. Heslin, MD, MSHA, Chief, Section of Surgical Oncology, University of Alabama at Birmingham (UAB) Medical Center, ...
SIDEBAR: Research Groups in South America
Although cancer research in South America has been largely led by the pharmaceutical industry, a number of independent research groups are active in the region. Peru: GECOPERU and INEN The Peruvian Oncology Clinical Studies Group (Grupo de Estudios Clínicos Oncológicos Peruano, or GECOPERU...
A Vision of Independent Clinical Research in South America
Clinical research is vital for the development and improvement of methods designed to prevent and treat cancer. The majority of clinical trials take place in the developed world through sponsored pharmaceutical research companies.1 The corresponding lack of research in developing countries results...
Ramucirumab for Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
On April 21, 2014, ramucirumab (Cyramza) was approved for use as a single agent in the treatment of patients with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with disease progression on or after prior treatment with fluoropyrimidine- or platinum-containing...
Connecting to ASCO Through the State Affiliate Council
ASCO’s State Affiliate Council is composed of the State Society Presidents and/or designated physician Council Representatives as well as the Executive Directors of each state and/or regional oncology society. The Council convened in late February to address the most relevant issues affecting...
Schwartz Center Rounds® Programs Foster Clinical Teamwork and Enhance Patient Care
In the fall of 1994, 40-year-old Kenneth B. Schwartz, a health-care lawyer, was diagnosed with lung cancer. Radiation and chemotherapy failed to stop progression of the disease, and 10 months later he died. During his treatment, Mr. Schwartz wrote about the ordeal of coming to grips with the...
Irving Bone Marrow Transplant Unit Opens at NewYork-Presbyterian/Columbia
New York-Presbyterian/Columbia University Medical Center has opened the Irving Bone Marrow Transplant Unit, a state-of-the-art facility for comprehensive bone marrow transplant (BMT) care. The new unit features 18 inpatient rooms, a high-tech nurses station for individual patient monitoring, and a...
Becky L. DeKay, MBA, Becomes President of ACCC
Becky L. DeKay, MBA, became President of the Association of Community Cancer Centers (ACCC) at its 40th Annual National Meeting in April. She is Director of Oncology Services at the Feist-Weiller Cancer Center at Louisiana State University (LSU) Health Shreveport, in Louisiana. “I am honored to...
Improving Quality of Life in Cancer Survivors
The number of cancer survivors has been steadily increasing in recent years. According to the Ministry of Health National Cancer Registry, in 2010 there were 254,000 cancer survivors in Israel (3.3% of the population) compared with 15,700 (0.4% of the population, P < .005) in 1975.1 Forty years...
Ongoing Clinical Trials Actively Recruiting Patients With Ovarian or Cervical Cancers
The information contained in this Clinical Trials Resource Guide includes details of actively recruiting clinical studies of patients with gynecologic and breast cancers. It also includes the Family Caregiver Palliative Care Intervention study, which is investigating interventions to support...
Thirty Years of Effort Has Led to the Mainstreaming of Integrative Medicine in Oncology Care
When Barrie R. Cassileth, MS, PhD, began researching complementary medicine and its potential for use in oncology care over 30 years ago, not much was known about the importance of complementary therapies for the well-being of patients with cancer. She chose to conduct her doctoral dissertation...
Surgical Resection of Newly Diagnosed Glioblastoma: What Is the Standard of Care?
The neurosurgeon is often the gateway provider when patients present with what on magnetic resonance imaging (MRI) appears to be a new glioblastoma. Because histology-based diagnosis is a prerequisite for initiating standard therapy with radiation and chemotherapy, the first question that the...
The Role of Psychosocial Supportive Services in Palliative Care
More than 2 decades ago, Deane L. Wolcott, MD, helped develop comprehensive patient-centered psycho-oncology care in cancer centers across the country. Today, many aspects of that patient-centered care, including psychiatric, dietary, pain management, cancer rehabilitation medicine, survivorship,...
Setting a ‘Moon Shots’ Goal to Drastically Reduce Cancer Mortality Over the Next Decade
In 2012, just 1 year after taking the reins as President of The University of Texas MD Anderson Cancer Center, Ronald A. DePinho, MD, announced his plans to launch the Moon Shots Program, the most ambitious endeavor undertaken by the cancer center to dramatically accelerate the pace of reducing...
James P. Allison, PhD, Receives 2014 Canada Gairdner International Award
The Gairdner Foundation of Canada has named James P. Allison, PhD, for one of its 2014 Canada Gairdner International Awards. Dr. Allison is Chair and Professor of Immunology at The University of Texas MD Anderson Cancer Center in Houston. The honor, announced recently by the Gairdner Foundation,...
Shelagh Tippet-Fagyas Named President of The Leukemia & Lymphoma Society of Canada
The Leukemia & Lymphoma Society recently announced that its Canadian affiliate, The Leukemia & Lymphoma Society of Canada, has named Shelagh Tippet-Fagyas as its new President. Ms. Tippet-Fagyas will lead the Canadian Society in its efforts to find cures and ensure access to therapies for...
ASCO Launches New Resources for Providers and Patients to Address Link Between Obesity and Cancer
As the obesity epidemic takes its toll on the nation’s health, ASCO is making strides to address this growing concern as it relates to cancer. ASCO has developed a suite of educational resources designed to help oncology providers educate their patients about the negative effects of obesity on...
American Society of Clinical Oncology Honors Researchers, Patient Advocates, and Leaders of the Global Oncology Community
Leaders in cancer care will be recognized as part of the American Society of Clinical Oncology Special Awards Program at the 2014 ASCO Annual Meeting. The Special Awards recognize the dedication and significant contributions of researchers, patient advocates, and leaders of the global oncology...
Project Data Sphere: Megadata in the Cloud Could Speed Clinical Trials Here on Earth
Project Data Sphere, which launched on April 8, is a “giant digital laboratory, an enormous library containing data about tens of thousands of patients and hundreds of clinical trials, all of which will be in the public domain,” said Martin J. Murphy, Jr, DMedSc, PhD, FASCO, Chief Executive Officer ...
Michael S. Gordon, MD, Named Medical Director for Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare
Michael S. Gordon, MD, has been named the new Medical Director for the Virginia G. Piper Cancer Center Clinical Trials program at Scottsdale Healthcare in Phoenix. Dr. Gordon will oversee the center’s phase I clinical trials program. Virginia G. Piper Cancer Center Clinical Trials at Scottsdale...
Phase III Trial Reports Focused Ultrasound Reduces Cancer Pain
A phase III clinical trial has shown that noninvasive magnetic resonance-guided focused ultrasound treatment that heats the cancer within the bone, relieves pain and improves function for most patients when other treatment options are limited. The results were published recently in the Journal of...
Getting It Right in the End: Individualization of Care for Patients With Rectal Cancer
Data from trials conducted mostly in the 1970s and 1980s established the paradigm that optimal treatment of rectal cancer requires a combination of radiation therapy, chemotherapy, and surgery.1 Virtually all of these trials, however, demonstrated that radiotherapy added only to the local control...
Beyond the Cystoscope: Thinkers and Technicians
I have spent my career working with urologists. Over a long period of time, I have concluded that they are fine and interesting people who work hard, live well, support interesting hobbies, generally take good care of their families, and are very enjoyable company at parties. The recent discussion...
Demanding More From Clinical Trials
“The function of the formal controlled clinical trial is to separate the relative handful of discoveries that prove to be true advances in therapy from a legion of false leads and unverifiable clinical impressions, and to delineate in a scientific way the extent of and the limitations that attend...
Cancer Chemotherapy Use During Pregnancy
INSIDE THE BLACK BOX is an occasional column providing insight into the FDA and its policies and procedures. In this installment, National Toxicology Program scientists Kembra L. Howdeshell, PhD, and Michael D. Shelby, PhD, discuss a recently completed monograph that reviews the published data on...
Volasertib Granted Orphan Drug Designation for Acute Myeloid Leukemia
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to volasertib for acute myeloid leukemia. Volasertib is currently being evaluated in a phase III clinical trial for the treatment of patients aged 65 or older, with previously untreated AML, who are ineligible for...
FDA Proposes to Extend Its Tobacco Authority to Additional Tobacco Products, Including E-Cigarettes
On April 24, 2014, as part of its implementation of the Family Smoking Prevention and Tobacco Control Act signed by the President in 2009, the U.S. Food and Drug Administration (FDA) proposed a new rule that would extend the agency’s tobacco authority to cover additional tobacco products. Products ...
ASCO Releases Adapted Guideline on Screening, Assessment, and Care of Anxiety and Depressive Symptoms in Adults With Cancer
Detection of depression is suboptimal, and its severity is underestimated in the general population, but it is known psychiatric disorders are more common in patients with cancer than in those with any other chronic illness. Although studies in cancer patients have yielded varying figures, it is...
The Affordable Care Act: NCCN Panelists Rate It ‘Average’
Oncologists and third-party payers are already experiencing changes as a result of the Affordable Care Act, which earned an “average” rating by a panel of providers, payers, and patients assembled at the 19th Annual Conference of the National Comprehensive Cancer Network (NCCN) in Hollywood,...
Belinostat Moves Forward in Trials for Two Aggressive Cancers
In February, the U.S. Food and Drug Administration (FDA) granted belinostat (Beleodaq), a targeted histone deacetylase (HDAC) inhibitor, priority review status based on a pivotal phase II trial in peripheral T-cell lymphoma. Just 1 month later, researchers at the National Cancer Institute (NCI) in...
Workshops Train Community Cancer Center Nurses and Administrators to Implement Clinical Trials
A series of new workshops are teaching nurses and administrators from community hospital cancer programs how to promote, run, and improve their institutions’ clinical trials. The training focuses on specific skills and tasks, offers postcourse support and aims for long-term, measurable outcomes,...
Promoting Health Behaviors Among Cancer Survivors
Promoting healthy behaviors among cancer survivors is associated with improved quality of life according to many studies. But how to translate that evidence into community practice remains a huge question, and the need for answers is growing. It’s not only the lack of consensus on how to help...
FDA Approves Ramucirumab for Stomach Cancer
The U.S. Food and Drug Administration (FDA) has approved ramucirumab (Cyramza) to treat patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with disease progression on or after prior treatment with fluoropyrimidine- or platinum-containing chemotherapy....
NCCN Clinical Practice Guidelines in Oncology: 2014 Updates
At the 19th Annual Conference of the National Comprehensive Cancer Network (NCCN), held recently in Hollywood, Florida, NCCN Panel members presented updates for several tumor types, briefly summarized here. For a more complete description of all updates, visit www.nccn.org. Breast Cancer Guidelines ...
Reflecting on the Past Year and Looking Ahead to the Next
On assuming the Presidency of ASCO a year ago, I recognized that one of our greatest challenges as a professional society is helping the American public understand the value of cancer research, especially now, when scientific advances are accelerating but resources are contracting. This is partly...
